Compare Solaredge Technologies Inc (SEDG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs BIO-TECHNE Corp — how do they compare? Solaredge Technologies Inc trades at $32.59 (market cap $2.04B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 5.6× Solaredge Technologies Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Solaredge Technologies Inc for 34 Days and BIO-TECHNE Corp for 63 Days on average.
| SEDG | TECH | |
|---|---|---|
Market Cap | $2.04B | $11.37B |
Volume | 2,111,744 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $78.51 | $72.61 |
52-Week Low | $28.47 | $43.31 |
Typical Hold Time | 34 Days | 63 Days |
Enterprise Value | $1.90B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $32.47, down 4.61% on the day, amid a bearish technical outlook and mixed earnings performance. The company reported a net loss of $405.45M in 2025 with a negative net margin of -34.24%, though revenue grew to $1.18B. Analyst sentiment is cautious with a Hold consensus and a $37.75 price target, while recent news highlights legal investigations and volatility in the solar sector.
The outlook remains challenging due to persistent losses and competitive pressures, but long-term growth potential exists from AI data center initiatives targeting $2.4B revenue by 2029. Key risks include high debt, industry headwinds from borrowing costs, and ongoing legal probes. Investors should weigh the speculative growth narrative against fundamental weaknesses.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
